Other languages Veracyte, Inc.

Equities

VCYT

US92337F1075

Real-time Estimate Cboe BZX Other stock markets 11:41:06 2024-06-03 am EDT			5-day change	1st Jan Change
21.31 ^USD	+2.70%		0.00%	-22.03%

May. 07	Earnings Flash (VCYT) VERACYTE Posts Q1 Revenue $96.8M, vs. Street Est of $93.4M	MT
May. 07	Transcript : Veracyte, Inc., Q1 2024 Earnings Call, May 07, 2024

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer	May. 22
Veracyte to Participate in Upcoming Investor Conferences	May. 15
Veracyte: Q1 Earnings Snapshot	May. 07
Earnings Flash (VCYT) VERACYTE Posts Q1 Revenue $96.8M, vs. Street Est of $93.4M	May. 07
Transcript : Veracyte, Inc., Q1 2024 Earnings Call, May 07, 2024	May. 07
Veracyte Announces First Quarter 2024 Financial Results	May. 07
Veracyte, Inc. Reports Unaudited Consolidated Impairment of Long-Lived Assets for the First Quarter Ended March 31, 2024	May. 07
Veracyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07
Veracyte, Inc. Raises Earnings Guidance for the Full-Year 2024	May. 07
14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding	May. 06
New Study Shows Veracyte's Decipher Prostate Test is Prognostic for Prostate Cancer Progression among Patients Undergoing Active Surveillance	Apr. 23
Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024	Apr. 22
New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance	Apr. 22
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024	Apr. 16
Goldman Sachs Cuts Veracyte Price Target to $28 From $32, Maintains Buy Rating	Apr. 15
Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines	Feb. 27
Morgan Stanley Trims Veracyte's Price Target to $21 From $22, Keeps Underweight Rating	Feb. 26
Sector Update: Health Care Stocks Mixed Premarket Friday	Feb. 23
Needham Raises Price Target on Veracyte to $33 From $30, Maintains Buy Rating	Feb. 23
Veracyte's Q4 Loss Widens, Revenue Increases; Issues 2024 Revenue Outlook; Shares Down Pre-Bell	Feb. 23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Veracyte, Inc.

Equities

VCYT

US92337F1075

Other languages

Filters